Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: Adipose tissue specific CCL18 associates with cardiometabolic diseases in non-obese individuals implicating CD4+ T cells

Fig. 4

CCL18 induce adipocyte lipolysis via activation of T cells

(a) Adipocyte lipolysis measured by glycerol µmol/g of lipid/2 hours in different metabolic groups (n = 16 for healthy, n = 16 CVD, n = 12 T2D and n = 12 CVD + T2D). (b) Pearson correlations (r- and p-values) of CCL18 secretion and adipocyte lipolysis (n = 47). Fat pad lipolysis (c) and correlation of CCL18 secretion with fat pad lipolysis (d) (n = 42). (e) Schematic representation of the experimental set-up to evaluate T cell role in CCL18-mediated lipolysis induction. (f) in vitro adipocyte lipolysis measured as a FC in the glycerol release normalized to protein amount in adipocytes treated with the CM from T cells (n = 17). Empty and checkered bars represent the CM from T cells treated without and with CCL18 treatment, respectively. One-way ANOVA with multiple comparisons was used in (a) and (c) and the unpaired t-test was used in (f). *p < 0.05, **p < 0.01 and ****p < 0.0001. Cohort 1 was used in a – d. In vitro differentiated hASCs were used in f.

Back to article page